

The Effectiveness of Various Postpartum Depression Treatments and the Impact of Antidepressant Drugs on Nursing Infants

Dwenda Gjerdingen, MD, MS

Background: Postpartum depression is seen in approximately 13% of women who have recently given birth; unfortunately, it often remains untreated. Important causes for undertreatment of this disorder are providers' and patients' lack of information about the effectiveness of various treatments, and their concerns about the impact of treatment on nursing infants. This article presents research-based evidence on the benefits of various treatments for postpartum depression and their potential risks to nursing infants.

Methods: The medical literature on postpartum depression treatment was reviewed by searching MEDLINE and Current Contents using such key terms as "postpartum depression," "treatment," "therapy," "psychotherapy," and "breastfeeding."

Results and Conclusions: There is evidence that postpartum depression improves with antidepressant drug therapy, estrogen, individual psychotherapy, nurse home visits, and possibly group therapy. Of the more frequently studied antidepressant drugs in breastfeeding women, paroxetine, sertraline, and nortriptyline have not been found to have adverse effects on infants. Fluoxetine, however, should be avoided in breastfeeding women. By administering effective treatment to women with postpartum depression, we can positively impact the lives of mothers, their infants, and other family members. (J Am Board Fam Pract 2003;16:372–82.)

Postpartum depression, observed in approximately 13% of women who have recently given birth,¹ is the most prevalent serious complication of pregnancy. It is classified as a major depressive disorder and as such is characterized by a variety of mental and physical symptoms that produce significant distress and detrimental changes in life functions (Table 1). According to the postpartum onset modifier of major depressive disorder, depressive symptoms begin within the first 4 weeks after delivery; however, it has been shown that women continue to remain at risk for mental disorders even several months after delivery.²

Postpartum depression is distinguishable from other postpartum mental disorders. The transient "postpartum blues" occur in a majority of mothers at some time within the first 2 weeks after delivery and are characterized by dysphoria, mood lability, crying, anxiety, insomnia, poor appetite, and irritability.³ The more serious but relatively rare post-

partum psychosis (prevalence of 0.1%–0.2%),³ is associated with such symptoms as loose thought associations, hallucinations, delusions, and disorganized or catatonic behavior.

Although the consequences of postpartum depression are usually not as severe as those of postpartum psychosis, they can have a significant, negative impact on the lives of not only mothers but also other family members. Mothers themselves might experience physical, marital, parental, social, and vocational difficulties.⁴ Their depression can, in some cases, also adversely affect their infants; studies have noted associations between maternal depression and impaired maternal-infant interactions,⁵ cognitive and emotional development,⁶ and anxiety and lower self-esteem.⁷

Given the potential serious consequences of postpartum depression, it is imperative that health professionals caring for mothers of infants appropriately manage this disorder. A common barrier to providing adequate care is failure to recognize the problem in the first place. Therefore, the US Preventive Services Task Force has recently recommended that adults be screened for depression in clinical practices that have systems in place to as-

Submitted, revised, 18 March 2003.

From the Department of Family Practice & Community Health, University of Minnesota, St. Paul. Address reprint requests to Dwenda Gjerdingen, MD, 580 Rice St., St. Paul, MN 55103 (e-mail: dgjerdin@umphysicians.umn.edu).

Table 1. Symptoms and Diagnostic Criteria for Major Depressive Episode**Symptoms**

1. Depressed mood most of the day.
2. Markedly diminished interest or pleasure in all, or almost all, activities, most of the day.
3. Marked decrease or increase in appetite, resulting in significant unintentional weight loss or weight gain (ie, >5% body weight in 1 month).
4. Insomnia or hypersomnia .
5. Psychomotor agitation or retardation .
6. Fatigue or loss of energy.
7. Feelings of worthlessness or inappropriate guilt.
8. Decreased ability to think or concentrate.
9. Recurrent thoughts of death, or recurrent suicidal thoughts (with or without a plan).

Diagnostic Criteria

Five or more of the symptoms listed above, representing a change in baseline, present nearly every day for the same 2-week period, and producing clinically significant distress or change in functioning

Must include symptom 1 or 2.

Symptoms do not meet criteria for a mixed episode, and they are not due to drugs, another medical condition, or bereavement (unless prolonged; i.e., >2 months)

Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.

sure accurate diagnosis, effective treatment, and follow-up.⁸ In a study of 342 women, use of the Edinburgh Postnatal Depression Scale (EPDS) to screen for depression at approximately 6 weeks postpartum improved the rate of depression diagnosis from 3.7% to 10.7%.⁹ Although the EPDS is the most commonly used screening tool for postpartum depression in research studies,³ the Task Force suggests that screening with a simple 2-question tool, developed by Whooley et al (1997),¹⁰ may be as effective as longer instruments. The tool includes these questions: (1) "Over the past 2 weeks, have you felt down, depressed, or hopeless?" and (2) "Over the past 2 weeks, have you felt little interest or pleasure in doing things?"¹⁰ A positive response to either question indicates a positive screen and should be followed by an expanded history to confirm the diagnosis of depression.

Once the diagnosis of postpartum depression has been established, it should be treated using methods similar to those used for non-postpartum major depressive disorder. These consist of (1) patient education regarding depression, including the biologic basis of depression, treatment options, therapeutic and adverse effects of antidepressant drugs, desired duration of treatment (usually several months or longer), and the need for a healthy lifestyle and social support and (2) the selection of an active treatment modality (usually antidepressant medication and/or psychotherapy) through shared decision making between the patient and

provider.¹¹ Notably, the treatment of depression in the postpartum period may be more challenging than in other stages of life. Patients and physicians often have concerns about the use of psychotropic medications in breastfeeding women and, related to this, questions about other viable treatment options for breastfeeding women. Therefore, the purpose of this article is to review empirically based information about the effectiveness of various pharmacologic and nonpharmacologic treatment modalities for postpartum depression and antidepressant drug effects on nursing infants.

Methods

A literature search on treatments for postpartum depression (ie, drug therapy, individual and group therapy, and other support therapy) was performed by searching MEDLINE, 1966 to August 2002. The key search terms used were "postpartum depression," "postnatal depression," "puerperal depression," "treatment," "therapy," "drug therapy," "psychotherapy," and "breastfeeding." Current Contents was also searched from 1994 to August 2002 using the key terms "postpartum depression," "puerperal depression," "postnatal depression," "therapy," "psychotherapy," and "group therapy." Searches were mostly limited to randomized controlled trials. Secondary searches were performed using the bibliographies of review articles¹²⁻¹⁴ and other articles obtained through these search meth-

ods. This procedure yielded 74 articles reporting on 8 types of treatment: antidepressant drugs (4 articles) and their effects on breast milk and nursing infants (50 articles), hormonal treatment (8 articles), individual or group psychotherapy (7 articles), nurse home visits (2 articles), and other treatments, including phototherapy, massage therapy, and electroconvulsive therapy (3 articles). Alternative drugs are not discussed here, because information about the safety of these agents is variable. Prophylactic treatments are also not included, because the amount of information on this topic is sufficient for another review.

Results

Antidepressant Treatment

Numerous studies have found antidepressant drugs to be effective in treating general depression.¹⁵ Although newer antidepressants [eg, selective serotonin reuptake inhibitors (SSRIs)] are as efficacious as the older tricyclic antidepressants (TCAs), the SSRIs are the drugs of choice for treating depressive disorders because of their greater tolerability and their relative safety if taken in overdose.^{15,16} Common side effects for TCAs include anticholinergic effects, weight gain, sedation, and orthostatic hypotension, whereas adverse effects for SSRIs include nausea, anorexia, diarrhea, headache, anxiety, nervousness, insomnia, drowsiness, sexual dysfunction, and increased sweating.¹⁷

Less attention has been given to the efficacy of antidepressant medications for postpartum depression. Uncontrolled studies have typically shown improvement in postpartum depressive symptoms after treatment with antidepressants such as sertraline,¹⁸ fluvoxamine,¹⁹ and venlafaxine.²⁰ However, because depression normally improves over time even without treatment, it is difficult to know whether the improvement in depressive symptoms seen in these studies can be attributed to antidepressant drugs or other factors. A fourth study controlled for such factors by randomizing 87 subjects to 4 groups: fluoxetine or placebo plus 1 or 6 sessions of counseling. Results showed that fluoxetine was better than placebo, and 6 sessions of counseling were better than 1, but there was no added benefit to combining fluoxetine and multiple counseling sessions.²¹ This trial provides experimental evidence that antidepressant drug therapy is effective in treating postpartum depression.

Antidepressant Treatment in Breastfeeding Mothers

A deterrent to mothers' use of antidepressant medications in the postpartum period is concern about potential adverse effects on the nursing infant.²² Several studies have been conducted to inform these concerns. Table 2 reports infant serum levels of antidepressants and behavioral outcomes for breastfeeding newborns whose mothers were treated with a variety of antidepressants, including several SSRIs and TCAs. Infant serum levels of antidepressants, rather than breast milk concentrations, are reported, because serum levels are considered to be more direct determinants of drug exposure.¹³

For most of the infants in these studies, serum levels of antidepressant drugs were either not detectable or very low. Exceptions to this were relatively high infant levels of nefazodone in 1 infant⁶⁸ and fluoxetine in 3 other infants.^{32,33} In each of these cases, disconcerting symptoms were seen—eg, increased crying, vomiting, diarrhea, colic, and decreased sleep with fluoxetine,^{32,33} and drowsiness, lethargy, hypothermia, and poor feeding with nefazodone.⁶⁸ The infant whose mother had taken nefazodone was preterm, which may have contributed to the problem. Adverse clinical outcomes were also seen in 1 infant exposed to citalopram,²⁴ 2 infants exposed to doxepin,^{58,60} 1 infant exposed to nefazodone,⁶⁸ and infants from 3 additional studies with fluoxetine.^{27,29,31} The largest fluoxetine study compared 64 fluoxetine-treated mother-infant pairs with 38 non-treated mother-infant pairs. Statistically significant reductions in infant weight were seen in the fluoxetine group (average deficit, 392 g between 2 weeks and 6 months of age).²⁹ Given the various concerns regarding antidepressant treatment for breastfeeding women, the US Food and Drug Administration has not approved any antidepressant for use during lactation.⁴⁷

These studies provide helpful clinical information about antidepressant transmission to nursing infants, but their methodological weaknesses must also be considered. First, many of the studies listed in Table 2 used a very low sample size; in the majority of reports, only 1 or 2 infants are represented. Second, sampling and measurement methods vary between studies; older studies tend to use less sensitive methods. Third, nursing infants generally ingest relatively small amounts of these drugs—less than 1% of the maternal dose;⁷¹ con-

Table 2. Antidepressant Drug Therapy in Breastfeeding Mothers: Infant Serum Drug Levels and Behavioral Outcomes

Study	No. of Infants	Maternal Dose	Infant Age (weeks)	Infant Serum Drug Levels (Lower Limit of Detection)*	Adverse Infant-Related Clinical Outcomes
Selective Serotonin Reuptake Inhibitors (SSRIs)					
Citalopram (Celexa)					
Jensen et al, 1997 ²³	1	20 mg/day	8	7 ng/mL	None
Schmidt et al, 2000 ²⁴	1	40 mg/day	6	12.7 ng/mL	Uneasy sleep, normalized with dose reduction
Rampono et al, 2000 ²⁵	7	0.36 mg/kg/day (median)		Not detected; 2.3 ng/mL (1 ng/mL)	None
Spigset et al, 1997 ²⁶	3	20–40 mg/day	8–16	Not discussed	None
Fluoxetine (Prozac)					
Brent & Wisner, 1998 ²⁷	1	20 mg/day	2–3	61 ng/mL	Limp, unresponsive, cyanotic (mother also taking carbamazepine and buspirone)
Burch & Wells, 1992 ²⁸	1	20 mg/day	17	Not discussed	None
Chambers et al, 1999 ²⁹	64	Not given	2–24	Not discussed	Lower growth curves (average deficit of 392 g)
Hendrick et al, 2001 ³⁰	20	10–60 mg/day	0–31	Fluoxetine, <1–84 ng/mL; Norfluoxetine, <1 - 265 ng/mL (2 ng/mL)	None
Isenberg, 1990 ³¹	1	20 mg/day	20	Not discussed	Irritability
Kristensen et al, 1999 ³²	14	0.24–0.94 mg/kg/day	0–60	Not detected; 252 ng/mL (10 ng/mL)	Colic in 2 infants; irritability, crying, and poor feeding in 2 infants (one of these also had methadone exposure)
Lester et al, 1993 ³³	1	20 mg/day	24	Fluoxetine, 340 ng/mL; Norfluoxetine, 208 ng/mL	Crying, vomiting, diarrhea, and decreased sleep, problem reversed with formula feeding
Taddio et al, 1996 ³⁴	11	0.17–0.85 mg/kg/day	3–107	Not detected in the one infant sampled (1 ng/mL)	None
Yoshida et al, 1998 ³⁵	4	20–40 mg/day	4–40	Fluoxetine and nonfluoxetine not detectable (2 ng/mL)	None
Fluvoxamine (Luvox)					
Hendrick et al, 2001 ³⁶	5	100–150 mg/day	6–13	Not detected (1 ng/mL)	None
Piontek, 2001 ³⁷	2	300 mg/day	2–8	Not detected (2.5 ng/mL)	None, for up to 2–3 years after exposure
Wright et al, 1991 ³⁸	1	200 mg/day	12	Not discussed	None
Yoshida et al, 1997 ³⁹	1	100–200 mg/day	17	Not discussed	None
Paroxetine (Paxil)					
Hendrick et al, 2001 ³⁶	16	5–30 mg/day	2–26	Not detected (1 ng/mL)	None
Misri et al, 2000 ⁴⁰	23	10–40 mg/day	4–42	Not detected (0.1 ng/mL)	None
Ohman et al, 1999 ⁴¹	7	10–40 mg/day	6–30	Not discussed	None
Stowe et al, 2000 ⁴²	16	10–50 mg/day	4–55	Not detected (2 ng/mL)	None
Sertraline (Zoloft)					
Altshuler et al, 1995 ⁴³	1	100 mg/day	3–7	Not detected (0.5 ng/mL)	None
Dodd et al, 2001 ⁴⁴	10	50–150 mg/day		Not detected (2 ng/mL)	None
Epperson et al, 2001 ⁴⁵	14	25–200 mg/day	17–26	Not detected (2.5 ng/mL)	None
Hendrick et al, 2001 ³⁶	33	25–200 mg/day	2–60	Not detected in 28; 2–8 ng/mL in 2 (1 ng/mL)	None
Holland, 2000 ⁴⁶	6	Not discussed	12–16	Not discussed	Reduced breast milk supply
Stowe et al, 1997 ⁴⁷	11	25–150 mg/day	4–141	Sertraline, undetectable or <3 ng/mL; desmethyl-sertraline, undetectable or <10 ng/mL (1 ng/mL)	None
Wisner et al, 1998 ⁴⁸	9	50–200 mg/day	0–22	Sertraline, not detected or <64 ng/mL; N-desmethyl-sertraline, not detected or <68 ng/mL (2 ng/mL)	None
Tricyclic Antidepressants (TCAs)					
Amitriptyline (Elavil)					
Bader & Newman, 1980 ⁴⁹	1	100 mg/day	7	Not detected (10 ng/mL)	Not discussed
Breyer-Pfaff et al, 1995 ⁵⁰	1	175 mg/day	0–4	Not detected (5 ng/mL)	None
Brixen-Rasmussen et al, 1982 ⁵¹	1	75–100 mg/day	14–30	Not detected (5 ng/mL)	None

Table 2. Continued

Study	No. of Infants	Maternal Dose	Infant Age (weeks)	Infant Serum Drug Levels (Lower Limit of Detection)*	Adverse Infant-Related Clinical Outcomes
Erickson et al, 1979 ⁵²	1	150 mg/day	8–11	Not detected (28 ng/mL)	Not discussed
Pittard & O'Neal, 1986 ⁵³	1	100 mg/day	2–3	Not discussed	Not discussed
Yoshida et al, 1997 ⁵⁴	2	100–175 mg/day	4–34	Not detected in one, 7.5 ng/mL in one (0.1 ng/mL)	Probably none (1 infant was hypotonic before and after exposure)
Clomipramine (Anafranil)					
Schimmell et al, 1991 ⁵⁵	1	125 mg/day	1–5	9.8–45.4 (20 ng/mL)	None
Wisner et al, 1995 ⁵⁶	4	75–125 mg/day	2–19	Not detected or not quantifiable (10 ng/mL)	None
Yoshida et al, 1997 ⁵⁴	2	75–125 mg/day	20–56	Not detected in one; 3.2–5.5 ng/mL in one (0.1 ng/mL)	None
Desipramine (Norpramin)					
Stancer & Reed, 1986 ⁵⁷	1	300 mg/day	10–11	Not detected (1 ng/mL)	None
Doxepin (Sinequan)					
Frey et al, 1999 ⁵⁸	1	35 mg/day	1	Doxepin, 10 µg/L; <i>N</i> -desmethyldoxepin not detected (10 ng/mL)	Poor suckling and swallowing, drowsiness, hypotonia, vomiting, weight loss
Kemp et al, 1985 ⁵⁹	1	150 mg/day	6	Not detected (5 ng/mL)	None
Matheson et al, 1985 ⁶⁰	1	75 mg/day	8	Doxepin, 3 µg/L; <i>N</i> -desmethyldoxepin, 58–66 µg/L (7 ng/mL)	Sedation, respiratory depression
Imipramine (Tofranil)					
Erickson et al, 1979 ⁵²	1	150 mg/day	8	Not detected (28 ng/mL)	Not discussed
Sovner & Orsulak, 1979 ⁶¹	1	200 mg/day	4	Not discussed	None
Yoshida et al, 1997 ⁵⁴	4	75–150 mg/day	2–25	Not detected in 2; 0.6–7.4 ng/mL in two (0.1 ng/mL)	None
Nortriptyline (Pamelor)					
Altshuler et al, 1995 ⁴³	1	125 mg/day	3–7	Not detected (10 ng/mL)	None
Mammen et al, 1997 ⁶²	2	Not discussed	16–31	Nortriptyline not detected; <i>E</i> -10-hydroxynortriptyline, <4 (2 ng/mL)	None
Matheson & Skjaeraasen, 1988 ⁶³	1	75–100 mg/day	1	Not discussed	None
Wisner & Perel, 1991 ⁶⁴	7	50–80 mg/day	0–24	Nortriptyline, not detectable; 10-hydroxynortriptyline, 5–11 ng/mL in 2 infants (4–5 ng/mL)	None
Wisner & Perel, 1996 ⁶⁵	5	75–110 mg/day	4–10	Not detected (<4 ng/mL)	None
Wisner et al, 1997 ⁶⁶	7	60–150 mg/day	4–6	0–10 ng/mL in 6 term infants; 16 ng/mL in the single preterm infant (4 ng/mL)	None
Other Antidepressants					
Bupropion (Wellbutrin)					
Briggs et al, 1993 ⁶⁷	1	100 mg/day	56	Not detected (25 ng/mL)	None
Nefazodone (Serzone)					
Yapp et al, 2000 ⁶⁸	1	300 mg/day	7–10	1270 ng/mL (lower limits of detection not given)	Drowsiness, lethargy, hypothermia, and poor feeding (preterm infant)
Venlafaxine (Effexor)					
Ilett et al, 1998 ⁶⁹	3	3–8 mg/kg/day	2–24	Venlafaxine, not detected (4 ng/mL); <i>O</i> -desmethyl-venlafaxine, 23–225 ng/mL (3 ng/mL)	None
Ilett et al, 2002 ⁷⁰	7	225–300 mg/day	11–41	Venlafaxine, not detected; 5 ng/mL; <i>O</i> -desmethyl-venlafaxine, 1.5–5.7 ng/mL (1 ng/mL)	None

*Lower limits of detection are shown in parentheses (in nanograms per milliliter) when the specified drug was not detected in the infant's serum. Lower limits vary with the precision of the laboratory method. 'Safe' infant serum levels of antidepressants have not been established, in that safety profiles depend on the age of the infant (healthy term infants more than 10 weeks old have a lower risk of negative effects), the characteristics of the drug, and concentrations of its metabolites.¹³

sequently, their serum levels of antidepressants tend to be very low. However, infants' serum levels of antidepressants might not be representative of their brain levels, because brain tissue is very lipophilic. Fourth, most of the studies had relatively short-term follow-up, lasting weeks to months over the course of antidepressant treatment but not beyond the treatment period. An exception to this is the study by Piontek et al³⁷ of fluvoxamine-exposed infants, where no ill effects were seen after 2 to 3 years of follow-up.

Maternal antidepressant therapy carries risks for nursing infants, but untreated depression is also risky—for mothers and infants. Thus, for each patient, the risks and benefits of treatment must be carefully weighed. If the potential benefits are thought to be greater, paroxetine, sertraline, and nortriptyline could be considered as initial drug therapy options. Each of these medications has been studied in more than 20 mother-infant pairs, with no adverse infant-related events observed. Fluoxetine should be avoided, and citalopram, doxepin, and nefazodone used only cautiously, because adverse effects have been associated with their use. It is generally recommended that treatment be initiated with an SSRI because of ease of administration and low toxicity.¹⁴ If the patient responds to an initial trial of medication lasting 6 to 8 weeks, the same dose should be continued for at least 6 months after full remission is achieved.¹⁴

Hormonal Treatment

Women experience dramatic hormonal shifts with the birth of a child. During pregnancy, levels of endogenous glucocorticoids and estrogens increase, only to plummet after delivery, producing a transient hypoactivation of the hypothalamic-pituitary axis that lasts for weeks to months. Cizza et al⁷² demonstrated that the suppression of the hypothalamic-pituitary axis is more severe and lasts longer in women who develop postpartum blues or depression. In a study of 23 women with severe postpartum depression, 16 had serum estradiol levels below the threshold for gonadal failure.⁷³ It follows, then, that the postpartum administration of exogenous hormones might be useful in blunting hormonal and mood declines in women who suffer from postpartum mood disorders.

In 2 prospective observational studies, a benefit to sublingual estrogen treatment of postpartum depression was found after only 2 weeks of treat-

ment.^{73,74} These positive outcomes were substantiated in a randomized placebo-controlled trial of 61 depressed mothers. After 1 month, women in the treatment group (200 µg of transdermal 17β-estradiol administered daily) had fewer depressive symptoms than those in the control group, and this benefit persisted over the 6-month treatment period.⁷⁵ Estrogen may also be effective therapy for postpartum psychosis, according to a few case reports.^{76,77} In contrast, progesterone has not been shown to be beneficial in treating postpartum mood disorders,⁷⁸ and in fact may even be detrimental.⁷⁹

Additional trials should be conducted to confirm these findings and to evaluate the comparative benefit of hormonal versus antidepressant therapy for postpartum depression. Further research is also needed to assess the safety of estrogen treatment in the postpartum period, particularly as it relates to certain risks that are unique to or already increased in the postpartum period, such as decreased milk production in lactating women or thromboemboli.

Individual and Group Psychotherapy

Another approach to the treatment of postpartum depression is psychotherapy, administered as either an alternative or an adjunct to antidepressant drug therapy. Individual psychotherapy was found to be effective in 4 randomized controlled trials (Table 3). Therapy was administered either by experienced psychotherapists,⁸² trained health visitors,^{21,81} or both.⁸⁰ The number of psychotherapy sessions ranged from 6 to 12. The study by Appleby et al²¹ was unique in that it compared individual psychotherapy with antidepressant therapy (fluoxetine)—both of which, as noted above, were found to be effective. A separate trial showed the value of including the partner in psychotherapy sessions. Women whose partners had participated in several psychotherapy sessions had lower Edinburgh Postnatal Depression Scores at the final assessment (which occurred 10 weeks after the first session) than those whose partners had not participated (8.6 vs 14.7, respectively).⁸⁶

Group therapy for mothers with postpartum depression has demonstrated mixed results: 2 studies found a benefit,^{83,85} and 1 did not.⁸⁴ These inconsistent outcomes may have resulted from differences in the structure and/or content of the group therapy sessions. For example, in the 2 studies with

Table 3. Effects of Individual and Group Psychotherapy on Postpartum Depression

Study	Study design; n	Intervention	Outcome
Individual Therapy			
Appleby et al, 1997 ²¹	Randomized controlled trial; n = 87 women with PPD	4 treatment groups: fluoxetine or placebo, plus 1 or 6 sessions of counseling provided by trained health visitors and derived from cognitive behavioral therapy (included reassurance and practical advice about feelings of not coping, child care, and lack of enjoyable activities and practical support)	Six sessions of counseling were better than 1 (clinical interview schedule score difference = 38.7% at 12 weeks), and fluoxetine was better than placebo (score difference = 40.7% at 12 weeks). There was no advantage in combining fluoxetine and counseling
Cooper & Murray, 1997 ⁸⁰	Randomized controlled trial; n = 194 primiparous women with PPD	4 treatment groups: nondirective counseling (n = 48), cognitive-behavioral therapy (n = 42), dynamic psychotherapy (n = 48), and a control group (n = 54); therapy sessions occurred 1 hour/week for 10 weeks	Over the initial 10-week period, the 3 treatment groups showed greater improvement than the control group; however, by 9 months postpartum, there was no significant difference between groups
Holden et al, 1989 ⁸¹	Randomized controlled trial; n = 55 women with PPD	8 weekly counseling visits by health visitors trained to provide nondirective counseling (listening to clients' feelings, and encouraging them to make decisions based on their own judgment)	69% of women in the counseling group versus 38% in the control group had recovered after 3 months.
O'Hara et al, 2000 ⁸²	Randomized controlled trial; n = 120 women with PPD	12 weekly individual counseling sessions led by experienced psychotherapists (discussed losses & and interpersonal conflicts and affirmed clients' competence)	43.8% of women in the counseling group versus 13.7% controls had recovered after 3 months.
Group Therapy			
Chen et al, 2000 ⁸³	Randomized controlled trial; n = 60 women with PPD	4 weekly supportive group sessions comprising discussions about transition to motherhood, postpartum stress management, communication skills, life planning, and strategies for change	Intervention group members experienced significant declines in depression scores, whereas control group members did not (Beck Depression Inventory change: -6.14 versus -0.92, $P < .01$).
Fleming et al, 1992 ⁸⁴	Non-randomized controlled trial; n = 76 depressed & 76 non-depressed mothers	8 weekly unstructured support groups, facilitated by psychologists; mothers discussed childbirth experiences, mood, motherhood, changing spousal relationships, and returning to work versus staying home	While the entire sample showed an improvement in mood from 2 weeks to 5 months postpartum, there was no significant intervention effect.
Meager & Milgrom, 1996 ⁸⁵	Randomized controlled trial; n = 20 mothers with PPD	10-week group treatment program, included education (about PPD), cognitive-behavioral therapy, and homework for reinforcement	Depression scores dropped significantly in the experimental group (Edinburgh Postnatal Depression Scale difference: -9.0), but not in the control group (difference, 0.5).

positive outcomes,^{83,85} therapy sessions seemed to be more structured than in the study with negative outcomes (the former 2 studies offered education about such topics as postpartum depression, stress management, communication skills, and life planning, whereas the latter dealt with women's subjec-

tive views of childbirth, motherhood, and changing spousal relationships). More research is needed to determine whether group therapy may be helpful for certain populations of depressed mothers and, if so, the manner in which group therapy should be administered.

Nurse Home Visits

Another type of postpartum support that has been studied, particularly in Europe, is that provided through nurse or midwife home visits. Two randomized controlled trials have shown a benefit from this type of intervention. In the first, 41 depressed mothers were randomized to a control group or a treatment group; treatment group participants received 6 weekly counseling visits by a Child Health Clinic nurse, who acted as a supportive listener.⁸⁷ Compared with the control group, the treatment group experienced a higher rate of recovery from postpartum depression (80% vs 25%). The second trial evaluated the benefit of a nurse home visit program for 181 women with adverse family characteristics.⁸⁸ Visits were made every week for 6 weeks, then every other week for an additional 6 weeks. During their visits, nurses provided guidance on childcare issues, facilitated access to community services, and reinforced successes. Here too, the treatment group showed better outcomes, with Edinburgh Postnatal Depression Scores of 5.7, compared with 7.9 in the control group.

Other Treatments

In addition to the previously described treatments for postpartum depression, certain physical modalities, such as light therapy, massage therapy, and electroconvulsive therapy, have been tested on a limited basis. Light therapy, often used for seasonal affective disorder, was evaluated in 2 depressed women—one who had been depressed for more than 4 months and refused antidepressant medication and another who had been depressed for an unspecified length of time but had not responded to a trial of psychotherapy.⁸⁹ In both women, Hamilton Rating Scale for Depression scores fell markedly after 4 weeks of daily 30-minute phototherapy sessions (from 28 to 29 at baseline to 11 to 12 at follow-up). Field et al⁹⁰ evaluated massage therapy by randomizing 32 depressed adolescent mothers to relaxation or massage therapy, administered for 30 minutes on 2 consecutive days, for 5 weeks. Results showed that mothers in the massage group had less anxiety, less anxious behavior, and lower stress hormone levels after their sessions than did mothers in the relaxation therapy group. Electroconvulsive therapy, long used for non-postpartum depression, is also thought to be both effective and safe in the postpartum period.⁹¹ Larger controlled

studies on these and other nonpharmaceutical treatments for postpartum depression are needed to expand treatment options, particularly for breastfeeding women.

Summary

In conclusion, several treatments for postpartum depression have been found to be effective. These include individual psychotherapy and antidepressant drug therapy. Paroxetine, sertraline, and nortriptyline were among the most widely studied antidepressants for which no adverse effects on breastfeeding infants were reported. Other treatments that show promise in managing postpartum depression include estrogen therapy, nurse home visits, and possibly group therapy. More research is needed to identify additional effective treatments, particularly those that are safe for breastfeeding women. These treatments should be combined with patient education about the illness, the specific treatment selected, and other mechanisms for promoting health, such as social support and a healthy lifestyle.

References

1. O'Hara MW, Swain AM. Rates and risk of postpartum depression—a meta-analysis. *Int Rev Psychiatry* 1996;8:37–54.
2. Gjerdingen DK, Chaloner KM. The relationship of women's postpartum mental health to employment, childbirth, and social support. *J Fam Pract* 1994;38:465–72.
3. Steiner M. Perinatal mood disorders: position paper. *Psychopharmacol Bull* 1998;34:301–6.
4. Anonymous. Practice guideline for major depressive disorder in adults. American Psychiatric Association. *Am J Psychiatry* 1993;150 (4 Suppl):1–26.
5. Murray L, Fiori-Cowley A, Hooper R, Cooper P. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. *Child Dev* 1996;67:2512–26.
6. Beck CT. The effects of postpartum depression on child development: a meta-analysis. *Arch Psychiatr Nurs* 1998;12:12–20.
7. Politano PM, Stapleton LA, Correll JA. Differences between children of depressed and non-depressed mothers: locus of control, anxiety and self-esteem: a research note. *J Child Psychol Psychiatr* 1992;33:451–5.
8. Anonymous. Screening for depression: recommendations and rationale. *Am Fam Physician* 2002;66:647–50.
9. Georgiopoulos AM, Bryan TL, Wollan P, Yawn BP.

- Routine screening for postpartum depression. *J Fam Pract* 2001;50:117-2.
10. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression: two questions are as good as many. *J Gen Intern Med* 1997; 12:439-45.
 11. Culpepper L. The active management of depression. *J Fam Pract* 2002;51:769-76.
 12. Winans EA. Antidepressant use during lactation. *J Hum Lact* 2001;17:256-61.
 13. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. *Am J Psychiatry* 1996;153:1132-37.
 14. Wisner KL, Parry BL, Piontek CM. Postpartum depression. *N Engl J Med* 2002;347:194-9.
 15. Mulrow CD, Williams JW, Trivedi M, Chiquette E, Aguilar C, et al. Evidence report on treatment of depression—newer pharmacotherapies. *Psychopharmacol Bull* 1998;34:409-47.
 16. Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. *Am Fam Physician* 2003;67:547-54.
 17. Majeroni BA, Hess A. The pharmacologic treatment of depression. *J Am Board Fam Pract* 1998;11:127-39.
 18. Stowe ZN, Casarella J, Landry J, Nemeroff CB. Sertraline in the treatment of women with postpartum major depression. *Depression* 1995;3:49-55.
 19. Suri R, Burt VK, Altshuler LL, Zuckerbrow-Miller J, Fairbanks L. Fluvoxamine for postpartum depression. *Am J Psychiatry* 2001;158:1739-40.
 20. Cohen LS, Viguera AC, Bouffard SM, et al. Venlafaxine in the treatment of postpartum depression. *J Clin Psychiatry* 2001;62:592-6.
 21. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. *BMJ* 1997;314:932-6.
 22. Yoshida K, Kumar R. Breast feeding and psychotropic drugs. *Int Rev Psychiatry* 1996;8:117-24.
 23. Jensen PN, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. *Ther Drug Monit* 1997;19:236-9.
 24. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. *Biol Psychiatry* 2000;47:164-5.
 25. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. *Br J Clin Pharmacol* 2000; 50:263-8.
 26. Spigset O, Careborg L, Ohman R, Norstrom A. Excretion of citalopram in breast milk. *Br J Clin Pharmacol* 1997;44:295-8.
 27. Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. *Clin Pediatr (Phila)* 1998;37:41-4.
 28. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentration in human milk. *Pediatrics* 1992;86:676-7.
 29. Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. *Pediatrics* 1999;104(5):e61.
 30. Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. *Biol Psychiatry* 2001;50: 775-82.
 31. Isenberg KE. Excretion of fluoxetine in human breast milk [letter]. *J Clin Psychiatry* 1990;51:169.
 32. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. *Br J Clin Pharmacol* 1999;48:521-7.
 33. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. *J Am Acad Child Adolesc Psychiatry* 1993;32:1253-55.
 34. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. *J Clin Pharmacol* 1996;36:42-7.
 35. Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. *Br J Psychiatry* 1998;172: 175-8.
 36. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. *Br J Psychiatry* 2001;179:163-6.
 37. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. *J Clin Psychiatry* 2001;62:111-3.
 38. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk [letter]. *Br J Clin Pharmacol* 1991;31:209.
 39. Yoshida K, Smith B, Kumar RC. Fluvoxamine in breast-milk and infant development. *Br J Clin Pharmacol* 1997;44:210-1.
 40. Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. *J Clin Psychiatry* 2000;61:828-32.
 41. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. *J Clin Psychiatry* 1999;60:519-23.
 42. Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. *Am J Psychiatry* 2000;157:185-9.
 43. Altshuler LL, Burt VK, McMullen M, Hendrick V. Breastfeeding and sertraline: a 24-hour analysis. *J Clin Psychiatry* 1995;56:243-5.
 44. Dodd S, Stocky A, Buist A, Burrows GD, Norman TR. Sertraline analysis in the plasma of breast-fed infants. *Aust N Z J Psychiatry* 2001;35:545-6.

45. Epperson N, Czarkowski KA, Ward-O'Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. *Am J Psychiatry* 2001;158:1631-7.
46. Holland D. An observation of the effect of sertraline on breast milk supply [letter]. *Aust N Z J Psychiatry* 2000;34:1032.
47. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. *Am J Psychiatry* 1997;154:1255-60.
48. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. *Am J Psychiatry* 1998;155:690-2.
49. Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. *Am J Psychiatry* 1980;137:855-6.
50. Breyer-Pfaff U, Nill K, Entenmann KN, Gaertner HJ. Secretion of amitriptyline and metabolites into breast milk. *Am J Psychiatry* 1995;152:812-3.
51. Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. *Psychopharmacology* 1982;76:94-5.
52. Erickson SH, Smith GH, Heidrich F. Tricyclics and breast feeding [letter]. *Am J Psychiatry* 1979;136:1483-4.
53. Pittard WB, O'Neal W. Amitriptyline excretion in human milk. *J Clin Psychopharmacol* 1986;6:383-4.
54. Yoshida K, Smith B, Craggs M, Kumar C. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. *J Affect Disord* 1997;43:225-37.
55. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. *J Toxicol Clin Toxicol* 1991;29:479-84.
56. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. *J Clin Psychiatry* 1995;56:17-20.
57. Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum. *Am J Psychiatry* 1986;143:1597-600.
58. Frey OR, Scheidt P, von Brenndorff A. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. *Ann Pharmacother* 1999;33:690-3.
59. Kemp J, Ilett KF, Booth J, Hackett LP. Excretion of doxepin and N-desmethyldoxepin in human milk. *Br J Clin Pharmacol* 1985;20:497-9.
60. Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk [letter]. *Lancet* 1985;2:1124.
61. Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. *Am J Psychiatry* 1979;136:451-2.
62. Mammen O, Perel JM, Wheeler S. Antidepressants and breast-feeding. *Am J Psychiatry* 1997;54:1174-5.
63. Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline, and zuclophenthixol and between-breast differences in two patients. *Eur J Clin Pharmacol* 1988;35:217-20.
64. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. *Am J Psychiatry* 1991;148:1234-6.
65. Wisner KL, Perel JM. Nortriptyline treatment of breast-feeding women [letter]. *Am J Psychiatry* 1996;153:295.
66. Wisner KL, Perel JM, Findling RL, Hinnes RL. Nortriptyline and its hydroxymetabolites in breast-feeding mothers and newborns. *Psychopharmacol Bull* 1997;33:249-51.
67. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. *Ann Pharmacother* 1993;27:431-3.
68. Yapp P, Ilett KF, Kristensen JH, Hackett LP, Paech MJ, Rampono J. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. *Ann Pharmacother* 2000;34:1269-72.
69. Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. *Br J Clin Pharmacol* 1998;45:459-62.
70. Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. *Br J Clin Pharmacol* 2002;53:17-22.
71. Hoffbrand S, Howard L, Crawley H. Antidepressant drug treatment for postnatal depression. *Cochrane Database Syst Rev* 2001;(2):CD002018.
72. Cizza G, Gold PW, Chrousos GP. High-dose transdermal estrogen, corticotropin-releasing hormone, and postnatal depression [letter]. *J Clin Endocrinol Metab* 1997;82:704.
73. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17 β -estradiol: a preliminary study. *J Clin Psychiatry* 2001;62:332-6.
74. Ahokas AJ, Turtiainen S, Aito M. Sublingual oestrogen treatment of postnatal depression [letter]. *Lancet* 1998;351:109.
75. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. *Lancet* 1996;347:930-3.
76. Ahokas A, Aito M. Role of estradiol in puerperal psychosis. *Psychopharmacology (Berl)* 1999;147:108-10.
77. Ahokas A, Aito M, Turtiainen S. Association between oestradiol and puerperal psychosis. *Acta Psychiatr Scand* 2000;101:167-70.
78. Granger ACP, Underwood MR. Review of the role

- of progesterone in the management of postnatal mood disorders. *J Psychosom Obstet Gynaecol* 2001;22:49–55.
79. Lawrie TA, Hofmeyr GJ, DeJager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. *Br J Obstet Gynaecol* 1998;105:1082–90.
 80. Cooper PJ, Murray L. The impact of psychological treatments of postnatal depression on maternal mood and infant development. In: Murray L, Cooper PJ, editors. *Postpartum depression and child development*. London: Guilford Press, 1997.
 81. Holden JM, Sagovsky R, Cox JL. Counselling in a general practice setting: controlled study of health visitor intervention in treatment of postnatal depression. *BMJ* 1989;298:223–6.
 82. O'Hara MW, Stuart S, Gorman LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. *Arch Gen Psychiatry* 2000;57:1039–45.
 83. Chen CH, Tseng YF, Chou FH, Wang SY. Effects of support group intervention in postnatally distressed women: a controlled study in Taiwan. *J Psychosom Res* 2000;49:395–9.
 84. Fleming AS, Klein E, Corter C. The effects of a social support group on depression, maternal attitudes and behavior in new mothers. *J Child Psychol Psychiatry* 1992;33:685–98.
 85. Meager I, Milgrom J. Group treatment for postpartum depression: a pilot study. *Aust N Z J Psychiatry* 1996;30:852–60.
 86. Misri S, Kostaras X, Fox D, Kostaras D. The impact of partner support in the treatment of postpartum depression. *Can J Psychiatry* 2000;45:554–8.
 87. Wickberg B, Hwang CP. Counselling of postnatal depression: a controlled study on a population based Swedish sample. *J Affect Disord* 1996;39:209–16.
 88. Armstrong KL, Fraser JA, Dadds MR, Morris J. A randomized, controlled trial of nurse home visiting to vulnerable families with newborns. *J Paediatr Child Health* 1999;35:237–4.
 89. Corral M, Kuan A, Kostaras D. Bright light therapy's effect on postpartum depression. *Am J Psychiatry* 2000;157:303–4.
 90. Field T, Grizzle N, Scafidi F, Schanberg S. Massage and relaxation therapies' effects on depressed adolescent mothers. *Adolescence* 1996;31:903–11.
 91. Rabheru K. The use of electroconvulsive therapy in special patient populations. *Can J Psychiatry* 2001;46:710–9.